Our findings suggest that LC supplementation may have augmented SPARC secretion in the postmenopausal women who participated in the RT program, because such an effect was not observed in the PLA group participants who completed the same RT protocol
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
**The clinical part of the AngioSafe 1 T2D study includes an observational study, where exposure to, i.e., any GLP-1R agonist was assessed, and an interventional study, where the exposure to GLP-1R agonists only included liraglutide
If you currently have an Olympia tirzepatide prescription, talk to your provider about your options going forward
PMC 6901466
We encourage you to take our free assessment quiz to see if you qualify for prescription weight loss medications tailored to your needs: Take the Assessment Quiz
